Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists create extremely potent and improved derivatives of successful anticancer drug

17.09.2013
Scientists at The Scripps Research Institute (TSRI) have found a way to make dramatic improvements to the cancer cell-killing power of vinblastine, one of the most successful chemotherapy drugs of the past few decades.

The team’s modified versions of vinblastine showed 10 to 200 times greater potency than the clinical drug. Even more significantly, these new compounds overcome the drug resistance that emerges upon treatment relapse, which renders continued or subsequent vinblastine treatment ineffective in some patients.

The TSRI researchers expect that similar modifications will boost the effectiveness of vincristine, a closely related drug that is commonly used against childhood leukemias and Hodgkin’s disease.

“These new compounds should improve on what are already superb anticancer drugs,” said Dale L. Boger, who is the Richard and Alice Cramer Professor and Chair of the Department of Chemistry at TSRI. Boger and members of his laboratory reported the discovery in a paper recently published online ahead of print by the journal ACS Medicinal Chemistry Letters.

Anticancer Agents

Vinblastine and vincristine are natural products of a pink-flowered herb known as the Madagascar periwinkle. Although the leaves of the plant had been used in traditional medicines for a range of other conditions, from diabetes to hemorrhoids, drug researchers at Eli Lilly found in the 1960s that the two compounds showed excellent potential as anticancer agents.

Both were found to selectively kill cancer cells by a mechanism that many other cancer drugs, including taxol, epothilones, and colchicine, have followed since—they bind a cellular protein called tubulin in a way that interferes with the buildup and breakdown of tubulin-containing chains called microtubules—structural elements of cells that play a key role in cell division. When the normal dynamics of their microtubules are disrupted, fast-dividing cancer cells stop dividing and die.

Since the 1960s, vinblastine has been used successfully in combination with other chemotherapy drugs against lymphomas as well as testicular, ovarian, breast, bladder and lung cancers. Vincristine is routinely used in combination regimes against childhood acute lymphoblastic leukemia and non-Hodgkin lymphomas. Both compounds are presently isolated from cultivated fields of the plants that make them naturally, but in trace amounts (0.0001% of the dry leaf weight). Since they are plant-derived natural products, they cannot be accessed using existing biotechnology or genetic engineering methods and, prior to the TSRI efforts, they were viewed as far too complex to be prepare by laboratory organic chemistry techniques. The authors developed a remarkable three-step preparation from commercially available chemicals using chemistry that they invented specifically for this purpose.

A significant limitation of vinblastine and vincristine is that, with extended treatment, they may evoke a powerful form of drug resistance. This resistance comes from a doorkeeper-type molecule called P-glycoprotein (Pgp), which transports infiltrating drug molecules out of the cancer cells. As cancer cells evolve to produce more and more Pgp, drugs fail to reach effective concentrations in cells and cancerous growth resumes. For years, medicinal chemists have tried to find modified versions—“analogues”—of these drugs that would overcome Pgp-mediated resistance, but without success.

Developing Extraordinary Potency

Last year, however, in a landmark paper in Organic Letters, Boger and his colleagues described a broad new method for modifying organic compounds like vinblastine, and demonstrated the method by making previously inaccessible variants of the drug. “Although it is a versatile method, we developed it specifically so that we could start making these vinblastine analogues that couldn’t be made before,” Boger said.

As his team used the method to make more new vinblastine analogues, the scientists discovered a type of modification to the drug that limits its usual drop in potency against resistant, Pgp-overproducing cancer cells as compared to non-resistant cancer cells. For the new study, the team explored variations of that modification and eventually found several analogues that were as good at killing resistant cells as ordinary vinblastine is at killing non-resistant cancer cells.

These new analogues were also many times more potent than vinblastine against non-resistant cells—which are the kinds of cancer cells almost all patients have at diagnosis. The laboratory of a major drug company, Bristol-Myers Squibb, was able to repeat these results in a larger set of clinically important human tumor cell lines, and Boger’s team confirmed that the new analogues’ greater potency corresponds to their greater ability to bind to tubulin.

“The potency of these analogues is extraordinary—they show activity down at the 100 picomolar level [100 trillionths of a mole] against some cell lines,” said Boger. “So we have something here that’s really unique, and we discovered it only because of the novel chemistry we developed.”

The other contributors to the paper, “Potent Vinblastine C20’ Ureas Displaying Additionally Improved Activity Against a Vinblastine-Resistant Cancer Cell Line,” were the lead author Timothy J. Barker, and Katharine K. Duncan and Katerina Otrubova, all of TSRI at the time of the study.

Funding for the study came in part from the National Institutes of Health (grants CA042056, CA115526, CA165303).

About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8136
press@scripps.edu

Mika Ono | EurekAlert!
Further information:
http://www.scripps.edu

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

Nonstop Tranport of Cargo in Nanomachines

20.11.2018 | Life Sciences

Researchers find social cultures in chimpanzees

20.11.2018 | Life Sciences

When AI and optoelectronics meet: Researchers take control of light properties

20.11.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>